Article Figures & Data
Figures
- Figure 1.
SCNE and nimbolide reduced viability in CRC cells. HCT116 and HT29 cells were treated with different concentrations of SCNE (A) and nimbolide (B) for 48 h and the cell viability was measured by MTT assay. Data were expressed as mean±SEM of three independent experiments. *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001 indicate significant difference versus vehicle control.
- Figure 2.
SCNE and nimbolide decreased protein levels of HDACs and DNMTs in CRC cells. HCT116 and HT29 cells were treated with SCNE (40 and 75 μg/ml) and nimbolide (5 and 10 μM) for 48 h and 96 h, respectively. Expression of HDACs (A and B) and DNMTs (C and D) were determined by western blot. GAPDH and Lamin B1 were used as standards.
- Figure 3.
SCNE and nimbolide reduced HDAC and DNMT activity in CRC cells. HCT116 and HT29 cells were treated with SCNE (40 and 75 μg/ml) and nimbolide (5 and 10 μM) for 48 h and 96 h, respectively. HDAC (A and B) and DNMT (C and D) activity was measured by ELISA. Data are expressed as mean±SEM. *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001 indicate significant difference versus vehicle control.
- Figure 4.
SCNE and nimbolide treatment decreases promoter deacetylation and methylation of p16 in HCT116. Individual changes were examined using antibodies against specific marks: Histone H3 (acetyl K9+K14+K18+K23+K27) (A), Histone H3 (tri methyl K9) (B), Histone H3 (tri methyl K27) (C). *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001 indicate significant difference versus vehicle control.
- Figure 5.
SCNE and nimbolide increase expression of p16 transcripts in HCT116. Significant results are seen at the higher concentration of 75 mg/ml SCNE and 10 mM nimbolide compared to SAHA (A) and 5-aza (B). Data are expressed as the mean±SEM. *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001 indicate significant difference versus vehicle control.
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.